Imatinib: novel treatment of immune-mediated kidney injury.

The treatments for many autoimmune diseases are limited in efficacy, and long-term use is associated with severe adverse events. The tyrosine kinase inhibitors have proven to be well tolerated for long treatment periods, with minimal adverse events, in the oncology population. These agents have recently been used to treat autoimmune diseases. We review the potential mechanisms whereby tyrosine kinase inhibitors may modulate the immune response and inhibit fibrogenesis and discuss the current evidence for their use in the treatment of autoimmune diseases of the kidney.

[1]  W. Couser.  Basic and translational concepts of immune-mediated glomerular diseases. , 2012, Journal of the American Society of Nephrology : JASN.

[2]  R. Nagai,et al.  Efficacy of low-dose imatinib mesylate for cutaneous involvement in systemic sclerosis: a preliminary report of three cases , 2012, Modern rheumatology.

[3]  V. Kelley,et al.  Distinct roles of CSF-1 isoforms in lupus nephritis. , 2011, Journal of the American Society of Nephrology : JASN.

[4]  P. Koskinen,et al.  Early short-term imatinib treatment is sufficient to prevent the development of chronic allograft nephropathy. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  T. Akizawa,et al.  Nilotinib attenuates renal injury and prolongs survival in chronic kidney disease. , 2011, Journal of the American Society of Nephrology : JASN.

[6]  C. Chatziantoniou,et al.  Discoidin domain receptor 1 is a major mediator of inflammation and fibrosis in obstructive nephropathy. , 2011, The American journal of pathology.

[7]  J. Gordon,et al.  Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial , 2011, Annals of the rheumatic diseases.

[8]  E. Neilson,et al.  Mechanisms of tubulointerstitial fibrosis. , 2010, Journal of the American Society of Nephrology : JASN.

[9]  A. Marini,et al.  Abnormal phenotype of bone marrow plasma cells in patients with chronic myeloid leukemia undergoing therapy with Imatinib. , 2010, Leukemia research.

[10]  A. Zimmermann,et al.  Imatinib mesylate induces clinical remission in rheumatoid arthritis. , 2010, Joint, bone, spine : revue du rhumatisme.

[11]  D. Schroeder,et al.  Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. , 2010, American journal of respiratory and critical care medicine.

[12]  M. Mack.  Podocyte antigens, dendritic cells and T cells contribute to renal injury in newly developed mouse models of glomerulonephritis. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[13]  Hans-Peter Lipp,et al.  Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. , 2009, Current drug metabolism.

[14]  D. Nikolic-Paterson,et al.  Antibody blockade of c-fms suppresses the progression of inflammation and injury in early diabetic nephropathy in obese db/db mice , 2009, Diabetologia.

[15]  M. Kawaguchi,et al.  Preventive and therapeutic effects of imatinib in Wistar-Kyoto rats with anti-glomerular basement membrane glomerulonephritis. , 2009, Kidney international.

[16]  S. Goff,et al.  c-Abl-deficient mice exhibit reduced numbers of peritoneal B-1 cells and defects in BCR-induced B cell activation. , 2009, International immunology.

[17]  E. Buchdunger,et al.  Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. , 2008, European journal of pharmacology.

[18]  J. Kay,et al.  Imatinib mesylate treatment of nephrogenic systemic fibrosis. , 2008, Arthritis and rheumatism.

[19]  R. Marasca,et al.  Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor , 2008, Haematologica.

[20]  M. Koury,et al.  Chronic myeloid leukemia-associated membranoproliferative glomerulonephritis that responded to imatinib mesylate therapy. , 2007, Clinical nephrology.

[21]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[22]  J. Rintala,et al.  Early short-term platelet-derived growth factor inhibition prevents the development of chronic allograft nephropathy in experimental rat kidney transplantation. , 2006, Transplantation proceedings.

[23]  W. Vogel,et al.  Discoidin domain receptor 1 null mice are protected against hypertension-induced renal disease. , 2006, Journal of the American Society of Nephrology : JASN.

[24]  F. Magro,et al.  Long-standing remission of Crohn's disease under imatinib therapy in a patient with Crohn's disease. , 2006, Inflammatory bowel diseases.

[25]  F. M. Thomas,et al.  Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. , 2006, The Journal of clinical investigation.

[26]  G. Remuzzi,et al.  Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease. , 2006, Kidney international.

[27]  H. Hirakata,et al.  Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice. , 2005, Arthritis and rheumatism.

[28]  I. Shiraishi,et al.  Adoptive transfer of macrophages ameliorates renal fibrosis in mice. , 2005, Biochemical and biophysical research communications.

[29]  A. B. Lyons,et al.  Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. , 2005, Blood.

[30]  D. Douek,et al.  Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. , 2005, Blood.

[31]  M. Cooper,et al.  Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. , 2005, Journal of the American Society of Nephrology : JASN.

[32]  N. Donato,et al.  Imatinib mesylate (Gleevec, STI-571) suppresses cytokine production by normal T-cells activated through T-cell receptor (TCR) signaling , 2005 .

[33]  A. B. Lyons,et al.  Imatinib inhibits the functional capacity of cultured human monocytes , 2005, Immunology and cell biology.

[34]  E. Leof,et al.  The FASEB Journal • Research Communication Imatinib mesylate blocks a non-Smad TGF- � pathway and reduces renal fibrogenesis in vivo , 2022 .

[35]  J. Melo,et al.  Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro , 2004, Leukemia.

[36]  K. Manova,et al.  Critical Role for Kit-mediated Src Kinase But Not PI 3-Kinase Signaling in Pro T and Pro B Cell Development , 2004, The Journal of experimental medicine.

[37]  L. Zitvogel,et al.  Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo. , 2004, Blood.

[38]  T. Brümmendorf,et al.  Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. , 2004, Blood.

[39]  E. Taskinen,et al.  Chronic allograft nephropathy is prevented by inhibition of platelet-derived growth factor receptor: tyrosine kinase inhibitors as a potential therapy , 2003, Transplantation.

[40]  G. Superti-Furga,et al.  Phosphorylation of Bruton's tyrosine kinase by c-Abl. , 2002, Biochemical and biophysical research communications.

[41]  S. Klahr,et al.  Obstructive nephropathy and renal fibrosis. , 2002, American journal of physiology. Renal physiology.

[42]  R. Atkins,et al.  Macrophage accumulation at a site of renal inflammation is dependent on the M‐CSF/c‐fms pathway , 2002, Journal of leukocyte biology.

[43]  M. Gassmann,et al.  Viable c-Kit(W/W) mutants reveal pivotal role for c-kit in the maintenance of lymphopoiesis. , 2002, Immunity.

[44]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[45]  R. Atkins,et al.  PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. , 2001, Kidney international.

[46]  P. Zipfel,et al.  The c-Abl Tyrosine Kinase Is Regulated Downstream of the B Cell Antigen Receptor and Interacts with CD191 , 2000, The Journal of Immunology.

[47]  D. Robinson,et al.  The protein tyrosine kinase family of the human genome , 2000, Oncogene.

[48]  Eric O Long,et al.  Essential role of LAT in T cell development. , 1999, Immunity.

[49]  M. Fujimoto,et al.  CD19 regulates B lymphocyte responses to transmembrane signals. , 1998, Seminars in immunology.

[50]  M. Carroll,et al.  CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. , 1997, Blood.

[51]  F. Alt,et al.  Abnormal peripheral lymphocyte function in c-abl mutant mice. , 1996, Cellular immunology.

[52]  P. Tipping,et al.  Tumor necrosis factor production by glomerular macrophages in anti-glomerular basement membrane glomerulonephritis in rabbits. , 1991, Laboratory investigation; a journal of technical methods and pathology.

[53]  S. Goff,et al.  Mice homozygous for the abl m1 mutation show poor viability and depletion of selected B and T cell populations , 1991, Cell.

[54]  P. Tipping,et al.  Glomerular macrophages produce reactive oxygen species in experimental glomerulonephritis. , 1989, Kidney international.

[55]  A. Fogo,et al.  Imatinib therapy for non-infection-related type II cryoglobulinemia with membranoproliferative glomerulonephritis. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[56]  K. Mace,et al.  Progenitor Cells , 2012, Methods in Molecular Biology.

[57]  D. Harris,et al.  Macrophages in renal disease. , 2011, Journal of the American Society of Nephrology : JASN.

[58]  E. Leof,et al.  Noncanonical TGF-beta pathways, mTORC1 and Abl, in renal interstitial fibrogenesis. , 2010, American journal of physiology. Renal physiology.

[59]  S. Ziegler,et al.  Imatinib suppresses cryoglobulinemia and secondary membranoproliferative glomerulonephritis. , 2009, Journal of the American Society of Nephrology : JASN.

[60]  A. Azzará,et al.  Reduction of immunoglobulin levels during imatinib therapy of chronic myeloid leukemia. , 2008, Leukemia research.

[61]  C. Alpers,et al.  A new look at platelet-derived growth factor in renal disease. , 2008, Journal of the American Society of Nephrology : JASN.

[62]  H. Kantarjian,et al.  Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia , 2005, Leukemia.

[63]  Jonathan T. Pribila,et al.  Signal transduction events regulating integrin function and T cell migration , 2003, Immunologic research.

[64]  E. Arranz,et al.  Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia. , 2003, Haematologica.

[65]  K. Matsumoto.  Production of interleukin-1 in macrophage cultures from rats with nephrotoxic serum nephritis. , 1988, International archives of allergy and applied immunology.

[66]  C. Alpers,et al.  Renin-angiotensin System Blockade Is Renoprotective in Immune Complex–mediated Glomerulonephritis , 2022 .